PDF(Pubmed)
Abstract：
OBJECTIVE: This study investigated the safety and efficacy of sclerotherapy with intralesional bleomycin injection (IBI) for retrobulbar orbital low-flow vascular lesions under multi-slice computed tomography (CT) guidance.
METHODS: Between January 2010 and September 2021, consecutive patients with retrobulbar orbital low-flow vascular lesions who underwent CT-guided IBI at a tertiary centre in Taiwan were enrolled. Their medical records and imaging data were retrospectively collected.
RESULTS: This study enrolled 13 patients (7 male and 6 female patients; age range: 1-57 years; mean age: 25.9 years) with lymphatic malformation (LM, n = 4), venolymphatic malformation (n = 1), and venous malformation (VM, n = 8). The overall radiological response rate was 76.9% (10 of 13); the radiological response rate was 75.0% in the VM group (6 of 8) and 75.0% in the LM group (3 of 4). Moreover, 3 patients (23.1%) had minor complications and 1 (7.7%) had a major complication. The mean clinical and radiological follow-up was 8.3 months and no recurrence or progression was reported.
CONCLUSIONS: CT-guided IBI is an effective and relatively safe minimally invasive treatment for retrobulbar orbital low-flow vascular lesions, with an overall radiological response rate of 76.9% in a mean of 1.5 sessions and a low complication rate.
CONCLUSIONS: CT-guided sclerotherapy with IBI is a relatively safe, effective, and feasible alternative treatment option for retrobulbar orbital low-flow vascular lesions.
METHODS: Between January 2010 and September 2021, consecutive patients with retrobulbar orbital low-flow vascular lesions who underwent CT-guided IBI at a tertiary centre in Taiwan were enrolled. Their medical records and imaging data were retrospectively collected.
RESULTS: This study enrolled 13 patients (7 male and 6 female patients; age range: 1-57 years; mean age: 25.9 years) with lymphatic malformation (LM, n = 4), venolymphatic malformation (n = 1), and venous malformation (VM, n = 8). The overall radiological response rate was 76.9% (10 of 13); the radiological response rate was 75.0% in the VM group (6 of 8) and 75.0% in the LM group (3 of 4). Moreover, 3 patients (23.1%) had minor complications and 1 (7.7%) had a major complication. The mean clinical and radiological follow-up was 8.3 months and no recurrence or progression was reported.
CONCLUSIONS: CT-guided IBI is an effective and relatively safe minimally invasive treatment for retrobulbar orbital low-flow vascular lesions, with an overall radiological response rate of 76.9% in a mean of 1.5 sessions and a low complication rate.
CONCLUSIONS: CT-guided sclerotherapy with IBI is a relatively safe, effective, and feasible alternative treatment option for retrobulbar orbital low-flow vascular lesions.
摘要：
目的：本研究探讨多层螺旋CT（CT）引导下病灶内注射博来霉素（IBI）硬化治疗眼眶球后低流量血管病变的安全性和有效性。
方法：2010年1月至2021年9月，在台湾某三级中心接受CT引导IBI的连续眼眶球后低流量血管病变患者。回顾性收集他们的医疗记录和影像学资料。
结果：这项研究纳入了13例患者（男性7例，女性6例；年龄范围：1-57岁；平均年龄：25.9岁），患有淋巴畸形（LM，n=4),静脉淋巴畸形（n=1），和静脉畸形(VM，n=8)。总体放射学反应率为76.9％（13个中的10个）；VM组（8个中的6个）的放射学反应率为75.0％，LM组（4个中的3个）的放射学反应率为75.0％。此外，3例（23.1％）有轻微并发症，1例（7.7％）有严重并发症。平均临床和放射学随访为8.3个月，未报告复发或进展。
结论：CT引导下IBI治疗眼眶球后低流量血管病变是一种有效且相对安全的微创治疗方法，总体放射学反应率为76.9％，平均1.5个疗程，并发症发生率低。
结论：CT引导下的IBI硬化治疗是一种相对安全的，有效,眼眶球后低流量血管病变的可行替代治疗方案。
方法：2010年1月至2021年9月，在台湾某三级中心接受CT引导IBI的连续眼眶球后低流量血管病变患者。回顾性收集他们的医疗记录和影像学资料。
结果：这项研究纳入了13例患者（男性7例，女性6例；年龄范围：1-57岁；平均年龄：25.9岁），患有淋巴畸形（LM，n=4),静脉淋巴畸形（n=1），和静脉畸形(VM，n=8)。总体放射学反应率为76.9％（13个中的10个）；VM组（8个中的6个）的放射学反应率为75.0％，LM组（4个中的3个）的放射学反应率为75.0％。此外，3例（23.1％）有轻微并发症，1例（7.7％）有严重并发症。平均临床和放射学随访为8.3个月，未报告复发或进展。
结论：CT引导下IBI治疗眼眶球后低流量血管病变是一种有效且相对安全的微创治疗方法，总体放射学反应率为76.9％，平均1.5个疗程，并发症发生率低。
结论：CT引导下的IBI硬化治疗是一种相对安全的，有效,眼眶球后低流量血管病变的可行替代治疗方案。
